米非司酮联合依沙吖啶用于中期妊娠引产的临床观察

目的：观察米非司酮联合依沙吖啶终止孕16～28周妊娠的临床效果。方法：选择200例孕16～28周因妊娠合并症或并发症,胎儿畸形,死胎等要求终止妊娠的健康妇女,无引产禁忌证。随机选择112例应用米非司酮联合依沙吖啶经腹羊膜腔内注射引产（研究组）,另选88例单用依沙吖啶经腹羊膜腔内注射引产（对照组）,对两组临床情况,终止妊娠效果进行比较。结果：米非司酮联合依沙吖啶经腹羊膜腔内注射终止中期妊娠（研究组）引产时间明显短于对照组,差异有统计学意义（P〈0.001）,胎盘粘连的发生率为5.36%,明显低于对照组的14.77%,同时软产道损伤发生率及产后清宫刮出残留组织物的量也低于对照组。结论：米非司酮联合依沙吖啶经腹羊膜腔内注射应用于孕16～28周妊娠能缩短引产时间,减少出血,降低胎盘粘连的发生率及软产道损伤的发生,值得推广。

Clinical observation of mifepristone combined ethacridine in midtrimester induced labour

Objective： To observe the clinical effect of mifepristone combined ethacridine to terminate 16-28 weeks pregnancy. Methods： 200 cases of 16-28 weeks healthy pregnant women who had to terminate pregnancy due to pregnancy-related comorbidities or complications, fetal malformation, stillbirth with no abortion contraindications were chosen as study subjects. 112 cases were randomly assigned to abdominal intra-amniotic injection of mifepristone combined ethacridine for induced labor （study group）, the other 88 cases were given intra-amniotic injection of ethacridine alone for induced labor （control group）. The clinical situation and effect of termination of pregnancy were compared between the two groups. Results： Mid pregnancy induction time of the study group was significantly shorter than the control group （P0.001）. And the incidence of placenta accreta was 5.36% in the study group, which was significantly lower than that in the control group （14.77%）. In addition, the soft birth canal injury rate and residual tissue scrapings in postpartum curettage was also lower in the study group. Conclusion： Mifepristone and ethacridine abdominal intra-amniotic injection used in 16-28 weeks of pregnancy can shorten the induction time, reduce bleeding, reduce the incidence of placenta accreta and soft birth canal injury, thus it is worthy of clinical application.